Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT

Lancet

Volumn 349, Issue 9053, 1997, Pages 667-674

  Julian, D G ^a   Camm, A J ^b   Frangin, G ^c   Janse, M J ^d   Munoz, A ^c   Schwartz, P J ^e   Simon, P ^c  

^a Netherhall Gardens   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c SANOFI   (France)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOCRINE DISEASE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MORTALITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VALVULAR HEART DISEASE; VISUAL DISORDER;

EID: 0031038213     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)09145-3     Document Type: Article

References (43)

1. Impact Research Group. International mexiletine and placebo antiarrhythmic coronary trial: I report on arrhythmic and other findings. J Am Coll Cardiol 1984; 4: 1148-63.
2. Furburg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol 1983; 52: 32C-36C.
3. Gottlieb SH, Achuff SC, Mellits ED, et al. Prophylactic antiarrhythmic theapy of high-risk survivors of myocardial infarction: lower mortality at 1 month but not at 1 year. Circulation 1987; 75: 792-99.
4. The Cardiac Arrhythmias Suppression Trial (CAST) Investigators. Preliminary report: effect of encanide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J M ed 1989; 321: 406-12.
5. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J M ed 1992; 327: 227-35.
6. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16: 1711-18.
7. Ceremuzynski L, Kleczar E, Kreminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992; 20: 1051-62.
8. Cairns JA, Conolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations: the Canadian amiodarone myocardial infarction arrhythmia trial. Circulation 1991; 4: 550-57.
9. Schwartz PJ, Camm AJ, Frangin G, Janse MJ, Julian DG, Simon P. Does amiodiarone reduce sudden death and cardiac mortality after myocardial infarction? The European Myocardial Infarct Amiodarone Trial (EMIAT). Eur Heart J 1994; 15: 620-24.
10. Camm AJ, Julian DG, Janse MJ, et al. The European Myocardial Infarct Amiodarone Trial (EMIAT). Am J Cardiol 1993; 72: 95F-98F.
11. Ruberman W, Weinblatt E, Goldberg JD, et al. Ventricular premature beats and mortality after myocradial infarction. N Engl J M ed 1977; 297: 750-57.
12. Moss AJ, Davis HT, DeCamilla J, Bayer LW. Ventricular ectopic beats and their relation to sudden and nonsudden cardiac death after myocardial infarction. Circulation 1978; 60: 998-1003.
13. Bigger JT Jr, Flaiss JL, Kleiger J, et al. The relationship among ventricular arrhythmias, left ventricular dysfunction, and mortality in two years after myocardial infarction. Circulation 1984; 69: 250-58.
14. Pitt B. Sudden cardiac death: role of left ventricular dysfunction. Ann N Y A cad Sci 1982; 382: 218-28.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
16. Cox DR. Regression models and life-tables. J R Stat Soc Ser B 1972; 34: 1987-202.
17. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The early termination of clinical trials: causes, consequences, and control, with special reference to trials in the field of arrhythmias and sudden death. Circulation 1994; 89: 2892-907 and Eur Heart J 1994; 15: 721-38.
18. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The early termination of clinical trials: causes, consequences, and control, with special reference to trials in the field of arrhythmias and sudden death. Circulation 1994; 89: 2892-907 and Eur Heart J 1994; 15: 721-38.
19. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I introduction and design. Br J Cancer 1976; 34: 585-612.
20. Waldo AL, Camm AJ, DeRuyter H, et al. The SWORD trial. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design and methods. Am J Cardiol 1995; 75: 1023-27.
21. Waldo AL, Camm AJ, de Ruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12.
22. Yusuf S, Venkatesh G, Teo KK. Critical review of the approaches to the prevention of sudden death. Am J Cardiol 1993; 72: 51F-58F.
23. Teo K, Yusuf S, Furberg C. Effect of antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomised controlled trials. JAMA 1993; 270: 1589-95.
24. Greenberg HM, Dwyer EM Jr, Hochman JS, Steinberg JS, Echt DS, Peters RW. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Heart 1995; 74: 631-35.
25. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. CAST and beyond: implications of the Cardiac Arrhythmia Suppression Trial. Eur Heart J 1990; 11: 194-99 and Circulation 1990; 81: 1123-27.
26. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. CAST and beyond: implications of the Cardiac Arrhythmia Suppression Trial. Eur Heart J 1990; 11: 194-99 and Circulation 1990; 81: 1123-27.
27. Ellenbogen KA, O'Callaghan WG, Colavita PG, Smith MS, German LD. Cardiac function in patients on chronic amiodarone therapy. Am Heart J 1985; 110: 376-81.
28. Gottlieb SS, Riggio DW, Lauria S, et al. High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure. J Am Coll Cardiol 1994; 23: 560-64.
29. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J 1994; 15: 721-38 and Circulation 1994; 89: 2892-907.
30. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J 1994; 15: 721-38 and Circulation 1994; 89: 2892-907.
31. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989; 69: 1049-169.
32. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990; 82: 51-59.
33. Meyer BJ, Amann FW. Additional antianginal efficacy of amiodarone in patients with limiting angina pectoris. Am Heart J 1993; 125: 996-1001.
34. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variablity: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-65 and Eur Heart J 1996; 17: 354-81.
35. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variablity: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-65 and Eur Heart J 1996; 17: 354-81.
36. Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. JAm Coll Cardiol 1991; 18: 687-97.
37. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death: experimental basis and clinical observations for post myocardial infarction risk stratification. Circulation 1992; 85 (suppl 1): 171-91.
38. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991; 121: 158-71.
39. Harris L, McKenna WJ, Rowland E, et al. Side effects of long-term amiodarone therapy. Circulation 1983; 67: 45-51.
40. Newnham HH, Topliss DJ, Le Grand BA, Chosich N, Harper RW, Stockigt JR. Amiodarone-induced hyperthyroidism: assessment of the predictive value of biochemical testing and response to combined therapy using propylthiouracil and potassium perchlorate. Aust N Z J M ed 1988; 18: 37-44.
41. Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow up in 28 cases. Clin Endocrin 1987; 26: 227-37.
42. Honhloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern M ed. 1994; 121: 529-35.
43. Bashir Y, Sneddon JF, Paul VE, et al. A prospective study of the efficacy and safety of adjuvant metropolol and xamoterol in combination with amiodarone for resistant ventricular tachycardia associated with impaired left ventricular function. Am Heart J 1992; 124: 1233-44.